combination therapy

You have access
Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling
JAE JUN SIM, MIN HEE PARK, JEONG-HEUM BAEK, HAEJUN LEE, KEUN-YEONG JEONG and HWAN MOOK KIM

Anticancer Research August 2018, 38 (8) 4667-4676; DOI: https://doi.org/10.21873/anticanres.12772
You have access
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
KOICHI SAKAGUCHI, KATSUHIKO NAKATSUKASA, HIROSHI KOYAMA, MAKOTO KATO, AKIRA SAKUYAMA, TAKAYUKI MATSUDA, NOBUYUKI TSUNODA, IKUYA FUJIWARA, MASAHIDE YAMAGUCHI, HIROKI TANAKA, KAZUYOSHI ONISHI, MIE ONISHI, YUJI YOSHINO, TAKASHI KIKUCHI and TETSUYA TAGUCHI

Anticancer Research July 2018, 38 (7) 4073-4081; DOI: https://doi.org/10.21873/anticanres.12697
You have access
Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells
NAYOUNG KIM, MIN-JUNG KANG, SANG HYUB LEE, JUN HYUK SON, JI EUN LEE, WOO HYUN PAIK, JI KON RYU and YONG-TAE KIM

Anticancer Research June 2018, 38 (6) 3527-3533; DOI: https://doi.org/10.21873/anticanres.12624
You have access
In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma
KEVIN T. BUSH, AMELIE BOICHARD and IGOR F. TSIGELNY

Anticancer Research April 2018, 38 (4) 1967-1977;
You have access
Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells
GEUN-HYOUNG HA, DONG-YOUNG KIM, EUN-KYOUNG BREUER and CHUNG KWON KIM

Anticancer Research March 2018, 38 (3) 1303-1310;
You have access
Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice
KENTARO IGARASHI, KEI KAWAGUCHI, TASUKU KIYUNA, TAKASHI MURAKAMI, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, HIROYUKI TSUCHIYA and ROBERT M. HOFFMAN

Anticancer Research March 2017, 37 (3) 1005-1011;
You have access
Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial
CESARE GRIDELLI, ANTONIO CHELLA, GIUSEPPE VALMADRE, GIACOMO ALLEGRINI, MATTEO BRIGHENTI, PAOLO BIDOLI, ANTONIO ROSSI, PAOLO MAIONE, MARIA RITA MIGLIORINO, SERENA RICCIARDI and FILIPPO DE MARINIS

Anticancer Research December 2016, 36 (12) 6535-6540;
You have access
The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells
KAROLINA LAPINSKA, GENEVIEVE HOUSMAN, SHANNON BYLER, SARAH HEERBOTH, AMBER WILLBANKS, ANUJA OZA and SIBAJI SARKAR

Anticancer Research November 2016, 36 (11) 5731-5742;
You have access
TAS-102 an Emerging Oral Fluoropyrimidine
JIEZHONG CHEN, MEI HAN and MUHAMMAD WASIF SAIF

Anticancer Research January 2016, 36 (1) 21-26;
You have access
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine
TOKUNBO YEROKUN and LEYTE L. WINFIELD

Anticancer Research December 2015, 35 (12) 6419-6424;

Main menu

User menu

Search

combination therapy

Pages